Kanut Laoharawee
Department of Pediatrics,
Center for Genomic Engineering,
Masonic Cancer Center
University of Minnesota
Kanut Laoharawee is a graduate student in the Molecular Cellular Developmental Biology and Genetics Program at the University of Minnesota, Minneapolis, MN, USA. He is currently working under Dr. Branden Moriarity in the Department of Pediatrics Medical School at the University of Minnesota. Kanut received his Bachelor of Science in Clinical Laboratory from Chulalongkorn University, Bangkok, Thailand, and his Masters in Biological Sciences from the University of Minnesota, MN, USA.
Kanut’s Masters’ focus was on using Adeno Associated Viral (AAV) vector for in vivo gene therapy to treat a mouse model of mucopolysachharidosis type II (MPS II), an inherited lysosomal storage disorder. As a Ph.D. student in Dr. Moriarity’s Lab, Kanut continues his pursuit of a novel and effective therapy to treat lysosomal storage disorders, now by using CRISPR/Cas9 system to edit primary B cells ex vivo. His goal is to express a therapeutic -L-iduronidase (IDUA) enzyme and enable an adoptive transfer of the engineered B cells into a mouse model of Hurler syndrome as a novel, cell-based, enzyme-replacement therapy.
Publications:
CRISPR/Cas9-Mediated Genome Engineering of Primary Human B Cells.
Method Mol Biol. 2020 | PMID:32006415
Implication of ZNF217 in Accelerating Tumor Development and Therapeutically Targeting ZNF217-Induced PI3K-AKT Signaling for the Treatment of Metastatic Osteosarcoma
Mol Cancer Ther. Dec 2020 | PMID: 32999043
PLX3397 treatment inhibits constitutive CSF1R-induced oncogenic ERK signaling, reduces tumor growth, and metastatic burden in osteosarcoma
Bone. Jul 2020 | PMID: 32251854
ZFN-Mediated In Vivo Genome Editing Corrects Murine Hurler Syndrome
Mol Ther. Jan 2019 | PMID: 30528089
Engineering of Primary Human B cells with CRISPR/Cas9 Targeted Nuclease
Sci Rep. Aug 2018 | PMID: 30108345
Dose-Dependent Prevention of Metabolic and Neurologic Disease in Murine MPS II by ZFN-Mediated In Vivo Genome Editing
Mol Ther. Apr 2018 | PMID: 29580682
Prevention of Neurocognitive Deficiency in Mucopolysaccharidosis Type II Mice by Central Nervous System-Directed, AAV9-Mediated Iduronate Sulfatase Gene Transfer
Human Gene Ther. Aug 2017 | PMID: 28478695
Prevention of Neurocognitive Deficiency in Mucopolysaccharidosis Type II Mice by Central Nervous System-Directed, AAV9-Mediated Iduronate Sulfatase Gene Transfer.
Human gene therapy 08, 2017 | Pubmed ID: 28478695
Dose-Dependent Prevention of Metabolic and Neurologic Disease in Murine MPS II by ZFN-Mediated In Vivo Genome Editing.
Molecular therapy : the journal of the American Society of Gene Therapy 04, 2018 | Pubmed ID: 29580682
Engineering of Primary Human B cells with CRISPR/Cas9 Targeted Nuclease.
Scientific reports 08, 2018 | Pubmed ID: 30108345
ZFN-Mediated In Vivo Genome Editing Corrects Murine Hurler Syndrome.
Molecular therapy : the journal of the American Society of Gene Therapy 01, 2019 | Pubmed ID: 30528089
CRISPR/Cas9-Mediated Genome Engineering of Primary Human B Cells.
Methods in molecular biology (Clifton, N.J.) , 2020 | Pubmed ID: 32006415
PLX3397 treatment inhibits constitutive CSF1R-induced oncogenic ERK signaling, reduces tumor growth, and metastatic burden in osteosarcoma.
Bone Jul, 2020 | Pubmed ID: 32251854
Implication of ZNF217 in accelerating tumor development and therapeutically targeting ZNF217-induced PI3K-AKT signaling for the treatment of metastatic osteosarcoma.
Molecular cancer therapeutics Sep, 2020 | Pubmed ID: 32999043
关于 JoVE
版权所属 © 2024 MyJoVE 公司版权所有，本公司不涉及任何医疗业务和医疗服务。